Combination of | |
---|---|
Memantine | NMDA receptor antagonist |
Donepezil | Acetylcholinesterase inhibitor |
Clinical data | |
Trade names | Namzaric |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Memantine/donepezil, sold under the brand name Namzaric, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type.[1] It contains memantine, as the hydrochloride, a NMDA receptor antagonist; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor.[1] It is taken by mouth.[1]
Memantine/donepezil was approved for medical use in the United States in 2014.[2]
AChE inhibitor medications | |
---|---|
Other medications | |
Experimental BACE inhibitors |